Cambridge Investment Research Advisors, Inc. Taysha Gene Therapies, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 23,690 shares of TSHA stock, worth $118,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,690
Previous 23,490
0.85%
Holding current value
$118,450
Previous $33,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TSHA
# of Institutions
155Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$125 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$118 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$109 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$84.3 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$63 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $242M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...